HDT Bio Publishes Peer-Reviewed Preclinical Study Demonstrating Robust Immunological Response in Mothers and Newborns Following repRNA/LION™ Vaccination

Mar 24, 2023 | Press Releases

LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...

Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen — Tuberculosis

Feb 1, 2023 | Publications

Click here to view...

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis – Vaccines 2023

Feb 1, 2023 | Publications

Click here to view...

HDT Bio to Develop RNA Cancer Vaccines and Treatments with South Africa’s Pan African Cancer Research Institute (PACRI)

Jan 30, 2023 | Press Releases

Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...

UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology

Nov 30, 2022 | Press Releases

UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...